

AGM Chairman's address and CEO's presentation

Melbourne, Australia; 30 November 2021: Attached is the Chairman's address together with the CEO's presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

The AGM will be held online. Shareholders and proxyholders will be able to listen, view presentations, vote and ask questions during the meeting in real-time through the Lumi virtual platform, for which details are available via <https://starpharma.com/2021agm>.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP[®] drug delivery and VivaGel[®]. Starpharma has developed VIRALEZE[™], an antiviral nasal spray that is registered for sale in the Europe, India and New Zealand, and available outside Australia in certain markets online. VIRALEZE[™] is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel[®] condom and VivaGel[®] BV. VivaGel[®] BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP[®], is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP[®] versions of existing drugs, particularly in the area of anti-cancer therapies. DEP[®] partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](https://starpharma.com) | [Twitter](#) | [LinkedIn](#)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

Chairman's Address
Starpharma Holdings Limited
Annual General Meeting
30 November 2021

Good morning,

On behalf of the Board of Directors, it is my pleasure to welcome you to Starpharma's 2021 Annual General Meeting.

Before I give my formal address, on behalf of the Board, I want to acknowledge the recent passing of our fellow Director, Peter Turvey, who stepped down as a Director in July this year due to illness. We extend our sincere condolences to his family and colleagues. Peter made an exceptional contribution to the company during his tenure and was a highly respected and regarded member of the biopharmaceutical industry. I know Peter was incredibly proud of Starpharma's development and was pleased to be involved with the development of medical products, and particularly oncology products, which have the potential to improve patient's lives and health outcomes.

I also want to thank upfront our CEO Dr. Jackie Fairley and the entire team at Starpharma for their commitment through such a challenging year. A year impacted by significant periods of lockdown and restrictions in Melbourne, and dealing with multiple regulators and clinical trials within a global pandemic background. Our team of around 50 people are highly skilled, innovative and passionate about making a difference. They operate at the cutting edge of science.

And while from an operational perspective, this has been a year of substantial progress, including the reporting of some very exciting new interim clinical results for DEP[®] cabazitaxel last week in prostate cancer patients, we nevertheless share with you the frustration with the current share price despite having recently achieved a multitude of valuable milestones.

This year, we continued to witness the devastating impacts of the COVID-19 pandemic following the emergence of multiple new and more severe variants, which required our community to innovate and adapt quickly to overcome the challenges posed by this global health crisis.

For Starpharma, it reinforced the value of our purpose and strategic focus as an organisation, which is to leverage the company's proprietary dendrimer platform technology to build a portfolio of high-value products and partnerships that address significant unmet patient need. It inspired our team to develop VIRALEZE[™], an innovative broad-spectrum antiviral nasal spray that can be used in situations where individuals may be at risk of being exposed to respiratory viruses, including coronavirus.

Throughout 2021, Starpharma expedited the development and commercialisation of VIRALEZE[™]. This involved rapid development, scale-up and manufacture of the product, while pursuing registrations and securing the right distributors in multiple regions worldwide. We registered VIRALEZE[™] in Europe, India, and New Zealand, and secured distribution agreements in the UK, Italy, and Vietnam, to enable launches of VIRALEZE[™] in pharmacies, online and in retail outlets in those regions. Starpharma established its own e-commerce store which has now shipped VIRALEZE[™] to consumers in more than 50 countries. You will hear from Jackie shortly regarding these developments, including an update on the commercial arrangements her team are working on across the globe.

During the year, we continued to test the antiviral agent in VIRALEZE[™] (SPL7013), against new coronavirus variants as they emerged, and other respiratory viruses, to understand the breadth of activity of the product. SPL7013, which already has a deep pedigree as a potent and broad spectrum antiviral compound, was shown to be virucidal against all four of the World Health Organisation's SARS-CoV-2 '*variants of concern*' – Delta, Alpha, Beta and

Gamma – as well as other respiratory viruses, including influenza and RSV, and pandemic viruses, SARS, and MERS in laboratory studies. New data on VIRALEZE™ and SPL7013 has also been published in prestigious international and peer reviewed scientific journals this year, highlighting the product's impressive antiviral and virucidal activity. Indeed, our collaborators at the prestigious Scripps Research Institute have emphasized the significance of this broad-spectrum activity across multiple variants.

COVID-19 is not the first pandemic the world has faced, and experts tell us it won't be the last. And while preventing a pandemic may not be entirely possible, across the world there is a recognition that we can better prepare ourselves with a range of interventions, like VIRALEZE™. With its advantages of broad-spectrum antiviral and virucidal activity, excellent safety profile and room temperature storage, VIRALEZE™ has great potential for providing an additional layer of protection against a range of respiratory viruses now and in future pandemic preparedness.

In parallel with our work on VIRALEZE™, Starpharma has also expanded the application of its cutting-edge DEP® drug delivery platform.

The company was excited to sign a new DEP® partnership agreement with leading international pharmaceutical company, Merck & Co Inc., in February. This is in addition to our established DEP® partnerships with AstraZeneca and Chase Sun, as well as several undisclosed partner programs. This growing stable of partnerships with leading companies demonstrate the optionality and high value of Starpharma's DEP® technology and the increasing attention from big pharma around the world.

Our DEP® collaborations enable partners to utilise Starpharma's drug delivery platform to develop value-added candidates with early-stage development costs partner funded and future licensing rights available for resultant DEP® based products. The partnerships we have built with our DEP® platform have the potential to create life-changing products for our patients, and long-term revenues for Starpharma by way of milestones and royalties.

Starpharma's commercial deal with AstraZeneca for instance, is an excellent demonstration of the potential progression for these partnered programs and the valuable opportunities associated with our DEP® technology.

It has been very exciting to see AstraZeneca accelerate and expand its clinical program for their novel anti-cancer drug, AZD0466, into a global multi-centre phase I/II trial this year, with a focus on hematological tumours *or* blood cancers. This expanded program includes a substantial increase in the number of trial sites globally, and this particular trial design means that the transition from phase I to phase II is seamless and significantly expedited. The study is actively enrolling patients at sites in the US, South Korea, and Australia, with plans to open in Europe as part of the global expansion announced earlier this year. This investment and expansion are being undertaken by AstraZeneca to facilitate development of AZD0466 with the objective of obtaining regulatory approval as soon as possible for specific indications of high unmet clinical need.

Starpharma was delighted to see that AstraZeneca and the prestigious MD Anderson Cancer Center will present AZD0466 at the world's premier hematology conference, ASH, in December, with two posters and presentations highlighting the clinical program and impressive performance of this innovative oncology agent as well as the benefits Starpharma's DEP® technology can deliver. We look forward to further updates as the program for AZD0466 progresses.

Internally, we continued to progress our three clinical stage DEP® products, DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan, through each of their phase II clinical development programs. Despite varying impacts of COVID-19 on each trial, all continued to recruit patients during the year and make good progress.

We are seeing impressive responses in patients treated with our DEP® products, demonstrating efficacy signals in a range of cancer types that are difficult to treat and in very

heavily pre-treated patients. These efficacy signals, which include significant reductions in measurable tumours for some patients, are particularly important for those who have failed multiple previous treatments and have few options. The results from these phase II trials have the potential to deliver vital treatment options for cancer patients and will be important milestones for the company by way of supporting new DEP[®] licences. We look forward to completing these programs.

Our Board, management, and Starpharma's partners have great confidence in the significant value of Starpharma's DEP[®] technology. This value lies not only in its ability to improve on the performance of existing and new drugs and to reduce side effects, but also its versatility and broad applicability to a wide range of medical products, including oncology agents, anti-infectives and so on.

To enable us to keep developing additional DEP[®] candidates towards the clinic and build value in our internal portfolio, Starpharma has deepened its development pipeline with a range of new DEP[®] candidates, including DEP[®] radiopharmaceutical and DEP[®] ADC (Antibody Drug Conjugate) products. The use of ADCs is an innovative and cutting-edge area in cancer therapy that continues to grow. Starpharma already has a number of partner programs including with Merck & Co Inc., and so the value of DEP[®] in this area is becoming well recognised. We look forward to progressing our partnered and internal programs further, in the year ahead.

Lastly with our VivaGel[®] portfolio – our commercial partners continued to roll out our products, including new launches of VivaGel[®] BV by Mundipharma in Nordic countries and South Africa, and the launch of the VivaGel[®] condom by LifeStyles in Europe. VivaGel[®] BV is now registered in more than 45 countries, and we continue to work closely with our partners to advance registrations and launches in other countries. The feedback from consumers and clinicians about VivaGel[®] BV is extremely positive.

I do want to thank my fellow board members for all their support. On the 1st of August 2021, we were pleased to appoint Lynda Cheng as an independent non-executive Director. Lynda Cheng has extensive experience as a finance executive, including as a CFO and has substantial non-executive and international experience.

Looking ahead this is an exciting time for Starpharma. We have an increasingly broad and high-value product pipeline, with multiple products in the clinic and on market, a very strong IP position and a growing suite of partners and commercial opportunities across our portfolio.

As we near the end of 2021, we are focused on progressing our DEP[®] programs, internal and partnered, and closing out a number of valuable distribution arrangements and product registrations for VIRALEZE™. As we look to 2022 and beyond, Starpharma remains focused on fulfilling its purpose and strategic objectives with further registrations, launches and revenue growth for VIRALEZE™ and VivaGel[®] products, and DEP[®] partnerships.

We take great pride in knowing that our product portfolio has real potential to create positive, even lifechanging, results for patient and customer health worldwide, all the while generating significant long-term value for our shareholders.

I thank shareholders for their support and look forward to the year ahead.

Thank you

Rob Thomas AO Chairman